RGC
Regencell Bioscience·NASDAQ
--
--(--)
--
--(--)
RGC fundamentals
During FY 2025, Regencell Bioscience (RGC) reported revenue of --, a YoY change of 0.00%. Net income was -3.58M, a YoY change of 17.85%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jul 1, 2018 | Jul 1, 2019 | Jul 1, 2019 | Jul 1, 2020 | Jul 1, 2020 | Jul 1, 2021 | Jul 1, 2021 | Jul 1, 2022 | Jul 1, 2022 | Jul 1, 2023 | Jul 1, 2023 | Jul 1, 2024 | Jul 1, 2024 | -- |
End Date | Jun 30, 2019 | Dec 31, 2019 | Jun 30, 2020 | Dec 31, 2020 | Jun 30, 2021 | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | -- |
Fiscal Year-End | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | -- |
Operating Expenses | 390.99K -- | 298.02K -- | 812.37K +107.77% | 368.46K +23.64% | 1.38M +70.04% | 3.66M +893.01% | 7.62M +451.47% | 3.43M -6.27% | 6.27M -17.64% | 2.31M -32.59% | 4.74M -24.50% | 1.98M -14.45% | 3.77M -20.41% | 3.77M -- |
Selling, General and Administrative Expenses | 162.77K -- | 105.08K -- | 426.14K +161.81% | 114.94K +9.38% | 943.04K +121.30% | 2.54M +2112.82% | 5.11M +441.40% | 2.08M -18.25% | 4.69M -8.10% | 1.83M -12.13% | 3.67M -21.77% | 1.47M -19.52% | 2.82M -23.12% | 2.82M -- |
Selling and Marketing Expenses | -- -- | -- -- | 114.21K -- | -- -- | 1.58K -98.62% | -- -- | 25.27K +1503.74% | -- -- | 262.66K +939.22% | 97.06K -- | 125.43K -52.25% | 7.33K -92.45% | 8.01K -93.61% | 8.01K -- |
General and Administrative Expenses | -- -- | -- -- | 311.93K -- | -- -- | 941.46K +201.81% | -- -- | 5.08M +439.62% | -- -- | 4.43M -12.81% | 1.73M -- | 3.55M -19.96% | 1.46M -15.43% | 2.81M -20.63% | 2.81M -- |
Research and Development Expenses | 228.22K -- | 192.93K -- | 386.23K +69.23% | 253.52K +31.40% | 438.32K +13.49% | 1.12M +339.96% | 2.51M +473.13% | 1.35M +21.05% | 1.58M -37.04% | 484.75K -64.10% | 1.07M -32.59% | 507.38K +4.67% | 948.29K -11.06% | 948.29K -- |
Operating Income | -390.99K -- | -298.02K -- | -812.37K -107.77% | -368.46K -23.64% | -1.38M -70.04% | -3.66M -893.01% | -7.62M -451.47% | -3.43M +6.27% | -6.27M +17.64% | -2.31M +32.59% | -4.74M +24.50% | -1.98M +14.45% | -3.77M +20.41% | -3.77M -- |
Non-Operating Income (Loss) | -- -- | -- -- | 0 -- | 34.62K -- | 34.62K -- | 89 -99.74% | 23.21K -32.94% | 114.28K +128303.37% | 211.34K +810.37% | 125.96K +10.22% | 373.50K +76.73% | 124.22K -1.38% | 185.77K -50.26% | 185.77K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | 0 -- | 34.62K -- | 34.62K -- | 89 -99.74% | 23.21K -32.94% | 114.28K +128303.37% | 211.34K +810.37% | 125.96K +10.22% | 373.50K +76.73% | 124.22K -1.38% | 185.77K -50.26% | 185.77K -- |
Pretax Income From Continuing Operations | -390.99K -- | -298.02K -- | -812.37K -107.77% | -333.85K -12.02% | -1.35M -65.78% | -3.66M -995.95% | -7.59M -463.92% | -3.32M +9.39% | -6.06M +20.18% | -2.19M +34.07% | -4.36M +28.03% | -1.85M +15.20% | -3.58M +17.85% | -3.58M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -390.99K -- | -298.02K -- | -812.37K -107.77% | -333.85K -12.02% | -1.35M -65.78% | -3.66M -995.95% | -7.59M -463.92% | -3.32M +9.39% | -6.06M +20.18% | -2.19M +34.07% | -4.36M +28.03% | -1.85M +15.20% | -3.58M +17.85% | -3.58M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | 0 -- | -67.36K -- | -148.61K -- | -87.86K -30.43% | -191.20K -28.66% | -119.27K -35.75% | -61.38K +67.90% | 0 +100.00% | 0 +100.00% | -- -- |
Net Income Attributable to Owners of the Company | -390.99K -- | -298.02K -- | -812.37K -107.77% | -333.85K -12.02% | -1.35M -65.78% | -3.59M -975.77% | -7.45M -452.88% | -3.23M +10.14% | -5.87M +21.15% | -2.07M +35.97% | -4.30M +26.73% | -1.85M +10.31% | -3.58M +16.68% | -3.58M -- |
Net Income Attributable to Common Stockholders | -390.99K -- | -298.02K -- | -812.37K -107.77% | -333.85K -12.02% | -1.35M -65.78% | -3.59M -975.77% | -7.45M -452.88% | -3.23M +10.14% | -5.87M +21.15% | -2.07M +35.97% | -4.30M +26.73% | -1.85M +10.31% | -3.58M +16.68% | -3.58M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -86.66K -- | 44.09K -- | 40.89K +147.19% | 48.88K +10.86% | -19.02K -146.51% | -19.02K -- |
Total Comprehensive Income | -390.99K -- | -298.02K -- | -812.37K -107.77% | -333.85K -12.02% | -1.35M -65.78% | -3.66M -995.95% | -7.59M -463.92% | -3.32M +9.39% | -6.15M +19.03% | -2.14M +35.40% | -4.32M +29.71% | -1.80M +15.74% | -3.60M +16.64% | -3.60M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | 0 -- | -- -- | 0 -- | -67.36K -- | -148.61K -- | -87.86K -30.43% | -191.20K -28.66% | -119.27K -35.75% | -61.38K +67.90% | 0 +100.00% | 0 +100.00% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -390.99K -- | -298.02K -- | -812.37K -107.77% | -333.85K -12.02% | -1.35M -65.78% | -3.59M -975.77% | -7.45M -452.88% | -3.23M +10.14% | -5.96M +19.99% | -2.02M +37.33% | -4.26M +28.48% | -1.80M +10.77% | -3.60M +15.44% | -3.60M -- |
Basic EPS | -0.04 -- | -0.03 -- | -0.08 -100.00% | -0.03 -- | -0.13 -62.50% | -0.29 -866.67% | -0.58 -346.15% | -0.25 +13.79% | -0.01 +98.28% | 0 +100.00% | -0.01 -- | 0 -- | -0.01 -- | -0.01 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -0.08 -- | -- -- | -0.13 -62.50% | -- -- | -0.58 -346.15% | -- -- | -0.01 +98.28% | 0 -- | -0.01 -- | 0 -- | -0.01 -- | -0.01 -- |
Diluted EPS | -0.04 -- | -0.03 -- | -0.08 -100.00% | -0.03 -- | -0.13 -62.50% | -0.29 -866.67% | -0.58 -346.15% | -0.25 +13.79% | -0.01 +98.28% | 0 +100.00% | -0.01 -- | 0 -- | -0.01 -- | -0.01 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -0.08 -- | -- -- | -0.13 -62.50% | -- -- | -0.58 -346.15% | -- -- | -0.01 +98.28% | 0 -- | -0.01 -- | 0 -- | -0.01 -- | -0.01 -- |
You can ask Aime
Did Regencell Bioscience beat or miss consensus estimates last quarter?What does Regencell Bioscience do and what are its main business segments?What is the revenue and EPS growth rate for Regencell Bioscience year over year?What were the key takeaways from Regencell Bioscience’s earnings call?What is Regencell Bioscience's gross profit margin?What were the key takeaways from Regencell Bioscience's earnings call?What is the market's earnings forecast for Regencell Bioscience next quarter?What factors drove the changes in Regencell Bioscience's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
